Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599144 | PMC |
| http://dx.doi.org/10.1093/jpids/piae105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complexity and Health Care Utilization in Infant ESKD.
Kidney360
September 2025
Department of Pediatrics, Division of Pediatric Nephrology, Baylor College of Medicine, Houston, TX, United States.
Background: Dialysis in neonates with ESKD is often associated with multiple comorbidities and the need for more intensified dialysis regimens. With recent advances in prenatal interventions and infant specific KRT, survival of neonates with ESKD has improved over the last decade. Little is known however about the impact on the health care system of improved survival in this population.
View Article and Find Full Text PDFThe hidden pandemic: changes in outpatient mental health care among French children and adolescents.
Eur Child Adolesc Psychiatry
September 2025
Center of Clinical Investigations, APHP.Nord, INSERM CIC1426, Robert Debré University Hospital, Paris, France.
The COVID-19 pandemic significantly worsened mental health (MH) challenges among young people. We aimed to assess changes in mental health-related outpatient care before and after the onset of the pandemic. In this nationwide cross-sectional study, we retrieved visits to general practitioners (GP) resulting in the coding of a MH disorder and/or the prescribing of any psychotropic medication for children aged 6 to 17 years, from January 1, 2016 to May 31, 2022 in France.
View Article and Find Full Text PDFCaregiver Social Needs and Outpatient Respiratory Outcomes in a Cohort of Children With Bronchopulmonary Dysplasia.
Pediatr Pulmonol
September 2025
Division of Pulmonary Medicine, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Objective: Bronchopulmonary dysplasia (BPD) is the most common cause of chronic lung disease in infancy. Caregivers often experience significant challenges in caring for these medically complex children. The purpose of this study was to determine feasibility of administering an electronic social determinants of health (SDoH) screening tool and to determine if caregiver social needs correlate with respiratory outcomes in children with BPD.
View Article and Find Full Text PDFAssessment of Pulmonary Function Tests in Patients with Hypothyroidism.
Ann Afr Med
September 2025
Department of Pediatrics, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Background And Aims: Hypothyroid patients often complain of shortness of breath, fatigue, and exercise intolerance. Both inspiratory and expiratory muscles' weakness is present, and the impairment of pulmonary function may be initiated at the subclinical stage of hypothyroidism. Hence, this study aimed to assess the pulmonary function tests (PFTs) in hypothyroid patients.
View Article and Find Full Text PDFUpadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review.
Clin Cosmet Investig Dermatol
September 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Rep
Purpose: Alopecia areata (AA) is a common, immune-mediated, non-scarring form of hair loss. Janus kinase inhibitors provide considerable insight into the treatment of severe AA. However, the efficacy and safety of upadacitinib treatment of adolescents and pediatric patients with severe AA is unclear, especially in those without concomitant atopic diseases.
View Article and Find Full Text PDF